http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
술후 방사성 요오드 사멸요법을 받은 갑상선암 환자들의 재발 관련인자에 관한 연구
고양석(Yang Seok Koh),윤정한(Jung Han Yoon),제갈영종(Yong Jong Jaegal) 대한두경부종양학회 2002 대한두경부 종양학회지 Vol.18 No.2
Background and Objective: Factors that are associated with the recurrence after radioactive iodine ablation therapy have not been identified yet. The aim of this study is to elucidate the factors that are related to the recurrence after thyroid surgery of the thyroid papillary cancer followed by radioactive iodine ablation therapy. Patients and Methods: Fifty four cases who had underwent thyroid cancer surgery and postoperative radioactive iodine ablation therapy were included in this study. Mean followup duration was 7 years. There were 41 women and 13 men. Data analysis was done retrospectively with medical record review. Chi-square test and Fisher's exact test was used for the statistical analysis. Results: Age over 40, capsular invasion, and loca invasion were the factors that were associated with the high rate of recurrence. But sex, size of the tumor, multiplicity and extent of the surgery were not related to the recurrence. Conclusion: Without the curative resection of the tumor, radioactive iodine ablation therapy cannot lower the recurrence rate. So aggressive resection of the thyroid papillary cancer is important.The more data accumulated and the longer the followup, the easier we can reveal the recurrence-related factors of postoperative radioactive ablation therapy.
Hwang, Hyeon Seok,Park, Mahn-Won,Yoon, Hye Eun,Chang, Yoon Kyung,Yang, Chul Woo,Kim, Suk Young,Cho, Jung Sun,Kim, Chan Joon,Park, Gyung-Min,Park, Chul-Soo,Choi, Yun-Seok,Koh, Yoon-Seok,Lee, Jong Min,S S. Karger AG 2014 American journal of nephrology Vol.40 No.4
<P>Abstract</P><P><B><I>Background/Aims:</I></B> Atrial fibrillation (AF) often coexists with acute myocardial infarction (AMI), and chronic kidney disease (CKD) is a major risk for AMI. However, the combined impact of CKD and AF on the mortality and morbidity in AMI population has not been determined. <B><I>Methods:</I></B> Between January 2004 and December 2009, a total of 4,738 AMI patients were enrolled prospectively. Patients were divided into four groups according to the combined status of CKD and AF. The primary endpoint was a combination of 5-year major adverse cardiac and cerebrovascular events (MACCE). <B><I>Results:</I></B> The prevalence of AF was significantly higher in CKD patients than in non-CKD patients (6.76 vs. 3.31%, p < 0.001). The highest cumulative event rate of MACCE and death was observed in patients with both CKD and AF (68.5 and 64.0%), respectively. In multivariable analyses, compared with patients with neither AF nor CKD, hazard ratios (HR) for composite of MACCE were 1.66 (95% CI, 1.14-2.41), 1.24 (95% CI, 1.06-1.46), and 2.10 (95% CI, 1.42-3.13) for patients with AF only, those with CKD only, and those with both CKD and AF, respectively (p for interaction = 0.935). Patients with both CKD and AF had a greatest risk for all-cause mortality (HR 2.54; 95% CI, 1.60-4.53), and the significant synergistic interaction was observed between CKD and AF (p for interaction = 0.015). <B><I>Conclusion:</I></B> The combined effect of AF and CKD on the risk of MACCE after an AMI is stronger than any separate condition, and it confers a synergistic effect on the all-cause mortality risk.</P><P>© 2014 S. Karger AG, Basel</P>
( Yang Won Min ),( Nam Jun Kim ),( Geum Youn Gwak ),( Yong Han Paik ),( Moon Seok Choi ),( Kwang Cheol Koh ),( Seung Woon Paik ),( Byung Chul Yoo ),( Joon Hyeok Lee ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background/Aim: The objective of this study was to compare the efficacy of lamivudine (LAM) and entecavir (ETV) in prevention of HBV reactivation in patients receiving systemic chemotherapy. Methods: A total of 554 non-hepatic cancer patients with HBsAg who underwent chemotherapy and received prophylactic antiviral therapy (454 with LAM and 100 with ETV) at the Samsung Medical Center between January 2008 and December 2010 were identified. Exclusion criteria were as following: late prophylaxis (not started within the first cycle of chemotherapy), any prior chemotherapy or/and antiviral therapy, follow-up less than 3 months, irregular medication, and chronic hepatitis B. Finally, clinical outcomes of 146 patients in LAM group and 40 in ETV group were compared. Hepatitis was defined as a 3 times increase in alanine aminotransferase (ALT) that exceeds 40 IU/L or an absolute increase of ALT to >100IU/L when compared with the baseline pre-chemotherapy value. Results: At baseline, there were no significant differences between two groups with regard to gender, aspartate aminotransferase, ALT, bilirubin, albumin, cancer type, purpose of chemotherapy, steroid use, and adjuvant radiotherapy. However, patients were younger (48.2 ± 9.4 vs. 51.5 ± 9.4, p=0.046), HBeAg seropositivity rate was higher (28.9% vs. 11.7%, p=0.010), and baseline HBV DNA level were higher [2401.0 IU/mL (<9->1.7x108) vs. 291.5 IU/mL (<9->1.7x108), p=0.006] in ETV group compared to LAM group. Five patients (2.7%) developed hepatitis: 4/146 (2.7%) and 1/40 (2.5%) in LAM and ETV group, respectively (p=1.000). Among them, 3 patients were accompanied by HBV DNA elevation (≥10-fold) only in LAM group (2.1% vs. 0.0%, p=1.000). During preemptive preemptive treatment, two in LAM group and one in ETV group developed hepatitis (1.4% vs. 2.5%, p=1.000). Severity of hepatitis was not different between two groups. Conclusions: LAM and ETV are comparable in efficacy in terms of prevention of hepatitis in HBsAg-positive patients receiving cancer chemotherapy.